mercoledì, 25 novembre 2020
28 Agosto 2018

FDA Updates Prescribing Information for Pembrolizumab and Atezolizumab in Urothelial Carcinoma

August 20, 2018 – On August 16, 2018, the U.S. Food and Drug Administration (FDA) updated the prescribing information for pembrolizumab and atezolizumab to require the use of an FDA-approved companion diagnostic test to determine programmed cell death ligand 1 (PD-L1) levels in tumor tissue from patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin therapy. The FDA approved two different companion diagnostic tests … (leggi tutto)